Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 2.1 (5-Year IF – 2.0)
Journal Citation Indicator (JCI) (2023) – 0.4
Scopus CiteScore – 3.7 (CiteScore Tracker 3.3)
Index Copernicus  – 161.11; MNiSW – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2018, vol. 27, nr 10, October, p. 1431–1439

doi: 10.17219/acem/73860

Publication type: review

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Immunopathogenesis of ophthalmological paraneoplastic syndromes: Recent findings

Monika Kordyś1,B,C,D,F, Joanna Przeździecka-Dołyk2,3,A,B,C,D,F, Anna Turno-Kręcicka2,E,F, Marta Misiuk-Hojło2,E,F

1 Student, Faculty of Medicine, Wroclaw Medical University, Poland

2 Department and Clinic of Ophthalmology, Faculty of Postgraduate Medicine, Wroclaw Medical University, Poland

3 Department of Optics and Photonics, Faculty of Fundamental Problems of Technology, Wrocław University of Science and Technology, Poland

Abstract

The aim of this study was to summarize the current knowledge of paraneoplastic syndromes involving eyes. The main interest was the immunopathogenesis of the abovementioned entities. A web search was conducted using Medline, Web of Science and Scopus engines. Key words concerning ocular paraneoplastic syndromes (OPS) such as: “ocular paraneoplastic syndrome”, “cancer-associated retinopathy”, “cancer-associated cone dysfunction”, “melanoma-associated retinopathy”, “bilateral diffuse uveal melanocytic proliferation”, and “paraneoplastic optic neuritis” were combined with “immunology”, “immune response”, “antibodies”, or “autoantibodies”. Numerous papers were found as a result of “ocular paraneoplastic syndrome” search and many of them matched the chosen criteria. We focused on the most recent papers – published in the last 5 years – and eventually, 92 items were found. Only several papers from each detailed category fulfilled both OPS and immunologic criteria. Site-specific paraneoplastic syndromes still remain a difficult clinical challenge. The immunopathogenesis of some of them seems to be more complex than previously thought.

Key words

ophthalmologic findings, optic neuropathy, immunopathogenesis, paraneoplastic syndrome, paraneoplastic retinopathy

References (55)

  1. Adamus G. Latest updates on antiretinal autoantibodies associated with vision loss and breast cancer. Invest Ophthalmol Vis Sci. 2015;56(3):1680–1688.
  2. Machida S, Ohguro H, Ishida K, Suzuki M, Kawagishi K. Recoverin-associated retinopathy secondary to Warthin tumor of parotid gland. Doc Ophthalmol. 2014;129(2):123–128.
  3. Turaka K, Kietz D, Krishnamurti L, et al. Carcinoma-associated retinopathy in a young teenager with immature teratoma of the ovary. J AAPOS. 2014;18(4):396–398.
  4. Saito W, Kase S, Ohguro H, Ishida S. Autoimmune retinopathy associated with colonic adenoma. Graefes Arch Clin Exp Ophthalmol. 2013;251(5):1447–1449.
  5. Dalin F, Adamus G, Yang S, et al. Aryl hydrocarbon receptor-interacting protein-like 1 in cancer-associated retinopathy. Ophthalmology. 2016;123(6):1401–1404.
  6. Weixler B, Oertli D, Nebiker CA. Cancer-associated retinopathy as the leading symptom in colon cancer. Clin Case Rep. 2016;4,(2):171–176.
  7. Yang S, Dizhoor A, Wilson DJ, Adamus G. GCAP1, Rab6, and HSP27: Novel autoantibody targets in cancer-associated retinopathy and autoimmune retinopathy. Transl Vis Sci Technol. 2016;5(3):1.
  8. Bhavsar KV, Hedges T, Thirkill CE, Reichel E. Paraneoplastic retinopathy associated with systemic follicular cell lymphoma. Ophthalmic Surg Lasers Imaging Retina. 2015;46(3):373–376.
  9. Adamus G, Bonnah R, Brown L, David L. Detection of autoantibodies against heat shock proteins and collapsin response mediator proteins in autoimmune retinopathy. BMC Ophthalmol. 2013;13:48.
  10. Adamus G, Yang S, Weleber RG. Unique epitopes for carbonic anhydrase II autoantibodies related to autoimmune retinopathy and cancer-associated retinopathy. Exp Eye Res. 2016;147:161–168.
  11. Morita M, Fukuhara T, Takahashi H, Maemondo M. Small cell lung cancer and progressive retinopathy. BMJ Case Rep. 2014;2014. doi: 10.1136/bcr-2014-205888
  12. Adamus G, Choi D, Raghunath A, Schiffman J. Significance of anti-retinal autoantibodies in cancer-associated retinopathy with gynecological cancers. J Clin Exp Ophthalmol. 2013;4(6):307.
  13. Saito M, Saito W, Kanda A, Ohguro H, Ishida S. A case of paraneoplastic optic neuropathy and outer retinitis positive for autoantibodies against collapsin response mediator protein-5, recoverin, and α-enolase. BMC Ophthalmol. 2014;14:5.
  14. Ogra S, Sharp D, Danesh-Meyer H. Autoimmune retinopathy associated with carcinoid tumor of the small bowel. J Clin Neurosci. 2014;21(2):358–360.
  15. Y. Makiyama, Kikuchi T, Otani A, et al. Clinical and immunological characterization of paraneoplastic retinopathy. Invest Ophthalmol Vis Sci. 2013;54(8):5424–5431.
  16. Finger ML, Thirkill CE, Borruat FX. Unusual paraneoplastic cause of vision loss: Combined paraneoplastic cone dystrophy and optic neuropathy. Arch Ophthalmol. 2012;130(5):660–662.
  17. Hargitai J, MacKay C, Behrens M, Odel JG, Hood DC, Gouras P. Auto-immune-like cone dystrophy. Doc Ophthalmol. 2004;109(3):215–221.
  18. Javaid Z, Rehan SM, Al-Bermani A, Payne G. Unilateral cancer-associated retinopathy: A case report. Scott Med J. 2016;61(3):155–159.
  19. Parc CE, Azan E, Bonnel S, Sahel JA, Kaplan J, Thirkill CE. Cone dysfunction as a paraneoplastic syndrome associated with retinal antigens approximating 40 KiloDalton. Ophthalmic Genet. 2006;27(2):57–61.
  20. Morita Y, Kimura K, Fujitsu Y, et al. Autoantibodies to transient receptor potential cation channel, subfamily M, member 1 in a Japanese patient with melanoma-associated retinopathy. Jpn J Ophthalmol. 2014;58(2);166–171.
  21. Lincoff N, Nadeem M, Younus Z, Thirkill CE. Exudative polymorphous vitelliform retinopathy: Importance of early recognition of the condition in patients with metastatic melanoma. Ophthalmol Ther. 2016;5(1):121–127.
  22. Wang Y, Abu-Asab M, Li W, Aronow ME, Singh AD, Chan C-C. Autoantibody against transient receptor potential M1 cation channels of retinal ON bipolar cells in paraneoplastic vitelliform retinopathy. BMC Ophthalmol. 2012;12:56.
  23. Aronow ME, Adamus G, Abu-Asab M, et al. Paraneoplastic vitelliform retinopathy: Clinicopathologic correlation and review of the literature. Surv Ophthalmol. 2012;57(6):558–564.
  24. Audemard A, de Raucourt S, Miocque S, et al. Melanoma-associated retinopathy treated with ipilimumab therapy. Dermatology. 2013;227(2):146–149.
  25. Xiong W-H, Duvoisin RM, Adamus G, Jeffrey BG, Gellman C, Morgans CW. Serum TRPM1 autoantibodies from melanoma associated retinopathy patients enter retinal on-bipolar cells and attenuate the electroretinogram in mice. PloS One. 2013;8(8):e69506.
  26. Dalal MD, Morgans CW, Duvoisin RM, et al. Diagnosis of occult melanoma using transient receptor potential melastatin 1 (TRPM1) autoantibody testing: A novel approach. Ophthalmology. 2013;120(12):2560–2564.
  27. Munk MR, Fernandes J, Mets M, Patel JD, Johnson ML, Jampol LM. Reversible nyctalopia and retinopathy in a patient with metastatic cancer treated with anti-heat shock protein 90 therapy. JAMA Ophthalmol. 2014;132(7):899–901.
  28. van Dijk EH, van Herpen CM, Marinkovic M, et al. Serous retinopathy associated with mitogen-activated protein kinase inhibition (binimetinib) for metastatic cutaneous and uveal melanoma. Ophthalmology. 2015;122(9):1907–1916.
  29. Mittal R, Cherepanoff S, Thornton S, Kalirai H, Damato B, Coupland SE. Bilateral diffuse uveal melanocytic proliferation: Molecular genetic analysis of a case and review of the literature. Ocul Oncol Pathol. 2015;2(2):94–99.
  30. Miles SL, Niles RM, Pittock S, et al. A factor found in the IgG fraction of serum of patients with paraneoplastic bilateral diffuse uveal melanocytic proliferation causes proliferation of cultured human melanocytes. Retina. 2012;32(9):1959–1966.
  31. Jansen JCG, van Calster J, Pulido JD, et al. Early diagnosis and successful treatment of paraneoplastic melanocytic proliferation. Br J Ophthalmol. 2015;99(7):943–948.
  32. Mets RB, Golchet P, Adamus G, et al. Bilateral diffuse uveal melanocytic proliferation with a positive ophthalmoscopic and visual response to plasmapheresis. Arch Ophthalmol. 2011;129(9):1235–1238.
  33. Jaben EA, Pulido JS, Pittock S, Markovic S, Winters JL. The potential role of plasma exchange as a treatment for bilateral diffuse uveal melanocytic proliferation: A report of two cases. J Clin Apher. 2011;26(6):356–361.
  34. Pulido JS, Flotte TJ, Raja H, et al. Dermal and conjunctival melanocytic proliferations in diffuse uveal melanocytic proliferation. Eye (Lond). 2013;27(9):1058–1062.
  35. Mudhar HS, Scott I, Ul‐Hassanet A, et al. Bilateral diffuse uveal melanocytic hyperplasia: Molecular characterization and novel association with bilateral renal papillary carcinoma. Histopathology. 2012;61(4):751–754.
  36. Rahimy E, Coffee RE, McCannel TA. Bilateral diffuse uveal melanocytic proliferation as a precursor to multiple systemic malignancies. Semin Ophthalmol. 2015;30(3):206–209.
  37. Gass JD, Gieser RG, Wilkinson CP, Beahm DE, Pautler SE. Bilateral diffuse uveal melanocytic proliferation in patients with occult carcinoma. Arch Ophthalmol. 1990;108(4):527–533.
  38. Lin P, Mruthyunjaya P. Retinal manifestations of oncologic and hematologic conditions. Int Ophthalmol Clin. 2012;52(1):67–91.
  39. Navajas EV, Simpson ER, Krema H, et al. Cancer-associated nummular loss of RPE: Expanding the clinical spectrum of bilateral diffuse uveal melanocytic proliferation. Ophthalmic Surg Lasers Imaging. 2011;42:e103–106.
  40. Yonekawa Y, Shildkrot Y, Eliott D. Inferior peripheral nonperfusion in bilateral diffuse uveal melanocytic proliferation. Ophthalmic Surg Lasers Imaging Retina. 2013;44(2):190–192.
  41. Barr CC, Zimmerman LE, Curtin VT, Font RL. Bilateral diffuse melanocytic uveal tumors associated with systemic malignant neoplasms: A recently recognized syndrome. Arch Ophthalmol. 1982;100(2):249–255.
  42. Margo CE, Pavan PR, Gendelman D, Gragoudas E. Bilateral melanocytic uveal tumors associated with systemic non-ocular malignancy: Malignant melanomas or benign paraneoplastic syndrome? Retina. 1987;7(3):137–141.
  43. Leys AM, Dierick HG, Sciot RM. Early lesions of bilateral diffuse melanocytic proliferation. Arch Ophthalmol. 1991;109(11):1590–1594.
  44. Adamus G, Brown L, Schiffman J, Iannaccone A. Diversity in autoimmunity against retinal, neuronal, and axonal antigens in acquired neuro-retinopathy. J Ophthalmic Inflamm Infect. 2011;1(3):111–121.
  45. Purvin V, Sundaram S, Kawasaki A. Neuroretinitis: Review of the literature and new observations. J Neuroophthalmol. 2011;31(1):58–68.
  46. Yang HK, Woo SJ, Park W-Y, Hwang J-M. Paraneoplastic neuromyelitis optica associated with ANNA-1 antibodies in invasive thymoma. BMC Ophthalmol. 2014;14:106.
  47. Rosencher L, Maisonobe T, Lavole A, Milleron B, Ferroir J-P. Neurologic paraneoplastic syndrome with anti-CV2/CRMP5 antibodies revealing a small cell lung cancer: Effectiveness of the lung cancer treatment [in French]. Rev Neurol (Paris). 2012;168(4):371–374.
  48. M. Figueroa, Guo Y, Tselis A, et al. Paraneoplastic neuromyelitis optica spectrum disorder associated with metastatic carcinoid expressing aquaporin-4. JAMA Neurol. 2014;71(4):495–498.
  49. Iyer A, Elsone L, Appleton R, Jacob A. A review of the current literature and a guide to the early diagnosis of autoimmune disorders associated with neuromyelitis optica. Autoimmunity. 2014;47(3):154–161.
  50. Verschuur CVM, van der Kooi AJ, Troost D. Anti-aquaporin 4 related paraneoplastic neuromyelitis optica in the presence of adenocarcinoma of the lung. Clin Neuropathol. 2015;34(4):232–236.
  51. Carboni G, Forma G, Bond AD, Adamus G, Iannaccone A. Bilateral paraneoplastic optic neuropathy and unilateral retinal compromise in association with prostate cancer: A differential diagnostic challenge in a patient with unexplained visual loss. Doc Ophthalmol. 2012;125(1):63–70.
  52. Al-Harbi T, Al-Sarawi A, Binfalah M, Dermime S. Paraneoplastic neuromyelitis optica spectrum disorder associated with stomach carcinoid tumor. Hematol Oncol Stem Cell Ther. 2014;7(3):116–119.
  53. Chao D, Chen WC, Thirkill CE, Lee AG. Paraneoplastic optic neuropathy and retinopathy associated with colon adenocarcinoma. Can J Ophthalmol. 2013;48(5):e116–120.
  54. Slamovits TL, Posner JB, Reidy DL, Thirkill CE, Keltner JL. Pancreatic neuroendocrine paraneoplastic optic neuropathy: Confirmation with antibody to optic nerve and hepatic metastasis. J Neuroophthalmol. 2013;33(1):21–25.
  55. Schoenberger SD, Kim SJ, Lavin P. Paraneoplastic optic neuropathy from cutaneous melanoma detected by positron emission tomographic and computed tomographic scanning. Arch Ophthalmol. 2012;130(9):1223–1225.
© Wroclaw Medical University